<![CDATA[FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases]]>
The FDA approved Nufymco (ranibizumab-leyk; Formycon AG, Zydus Lifesciences Ltd), an interchangeable ranibizumab biosimilar referencing Lucentis (Genentech, Novartis). According to a news release from the manufacturer, Nufymco can be used interchangeably …